Chair: 

Siddhartha Sankar Datta, Regional Adviser on Vaccine-preventable Diseases and Immunization programme, WHO Regional Office for Europe
Kamel Senouci, ADVAC Director, University of Geneva

The example of the COVID immunization policy in France, Brigitte Autran, Chair of the French Surveillance and Response Advisory Committee (Comité de Veille et d’Anticipation des Risques Sanitaires, COVARS) (25 minutes)
The example of the COVID immunization policy in Finland, Hanna Nohynek, Chair WHO SAGE, Secretary of the Finnish NITAG and Department of Health Security in the Finnish Institute for Health and Welfare (THL), Finland (25 minutes)

Brigitte Autran
Hanna Nohynek

Chair: 

Dr Naveen Thacker, member of the ADVAC Scientific Committee, the vice-chair of the International Collaboration of the Advanced Vaccinology Trainings (ICAVT), and the President of the International Pediatric Association (IPA) for the year 2021-2023
Dr Md Tanvir Hossen, Alumni 22nd ADVAC, Deputy Program Manager, EPI & Surveillance, Directorate General of Health Services, Ministry of Health & Family Welfare, Bangladesh

Prof T. Jacob John, Co-Chair of India Expert Advisory Group on Measles and Rubella Elimination (25 minutes).
Dr. Firdausi Qadri, Senior Scientist and Head, Mucosal Immunology and Vaccinology Unit Senior Director, Infectious Diseases Division, icddr,b, and Founder & Lead, Institute for developing Science and Health initiatives (ideSHi) (25 minutes).

Dr. Firdausi Qadri, Prof T. Jacob John & Dr Naveen Thacker (25 minutes)

General discussion and questions with the Alumni (45 minutes)

Chair: 

Joris Vandeputte, International Alliance for Biological Standardization
Kamel Senouci, ADVAC

Introduction by Joris Vandeputte
Update on the animal monkeypox:  Yoshi Nakazawa, US Centers for Disease Control and Prevention
Update on the human monkeypox:   Brett W. Petersen, US Centers for Disease Control and Prevention

Joris Vandeputte
Jean-Marie Okwo-Bele
Brett W. Petersen
Yoshi Nakazawa

Bridging studies – why and how?
Peter Dull, Bill & Melinda Gates Foundation

Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.

Panel discussion:  Strategies behind the variant adapted COVID-19 vaccines development
with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President   Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing   IFPMA, and other experts.

COVID-19 Vaccine Safety – Perspective from WHO’s Global Advisory Committee on Vaccine Safety
Presenter: Rita Helfand, Chair, Global Advisory Committee on Vaccine Safety, WHO, and Senior Advisor for Science, National Center for Emerging and Zoonotic Infectious Diseases, CDC

COVID-19 Vaccine Safety – US experience
Presenter: Tom Shimabukuro, Acting Director, Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Presidente: Professor Romina Libster, Fundación INFANT, Argentina y profesora del ADVAC

Disertantes:
Professor Cristiana Toscano, Federal University of Goiás, Brazil
Evidencia para orientar la decisión sobre los esquemas de refuerzos de la vacunación contra COVID-19 ¿Qué sabemos y qué no sabemos?

Professor Celia Alpuche, Instituto Nacional de Salud Publica, Mexico
Desafíos y complejidades en el proceso de toma de decisiones para la vacunación COVID-19: experiencia de América Latina

Discusion:
Professor Alejandro Cravioto, Universidad Nacional Autónoma de México y Presidente del SAGE

Chair: Professor Anna Durbin, Johns Hopkins Bloomberg School of Public Health, USA and Member of the ADVAC Scientific Committee

Président: Prof. Paul-Henri Lambert, Université de Genève et Membre du comité scientifique d’ADVAC

Chair: Dr Hanna Nohynek, National Institute for Health and Welfare, Helsinki, Finland and Member of the ADVAC Scientific Committee

Presenters:
Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
Booster versus 2+1 primary immunisation vaccination: Does it matter?

Dr Jerome Kim, International Vaccine Institute, Seoul, Republic of Korea
The booster in your future: when, what, and why?

The Immunological benefits of mRNA and potential applications
Presenter:  Barney Graham, previously with the National Institute of Health, USA

Regulatory approaches:  Issues and challenges, and questions to be asked by regulators
Presenter:  Philip Krause, Food & Drug Administration, USA

Dr Martin Friede, WHO will chair the meeting.

Dr Richard Mihigo, WHO Regional Office for Africa
Dr Magdalena Bastias, Immunization Department, Ministry of Health, Chile and member of the Global NITAG Network Steering Committee